Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4406MR)

This product GTTS-WQ4406MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF9 gene. The antibody can be applied in Tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3604
UniProt ID Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4406MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6605MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ9333MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ10871MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ13528MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRX-003
GTTS-WQ193MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ13619MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ2602MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ5457MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDA 1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW